Carrillo-Jimenez Rodolfo, Lamas Gervasio A, Hennekens Charles H
Department of Cardiology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA.
J Cardiovasc Pharmacol Ther. 2002 Oct;7(4):207-10. doi: 10.1177/107424840200700402.
The use of Human Immunodeficiency Virus (HIV) protease inhibitors as part of the Highly Active Antiretroviral Therapy (HAART) is associated with atherogenic dyslipoproteinemia, insulin resistance, hypertension and endothelial dysfunction, all of which contribute to premature coronary heart disease. These abnormalities appear to be associated with an increase in cardiovascular events in HIV-infected patients. Beneficial metabolic effects of anti-diabetic agents used in HIV-infected patients have been reported. The thiazolidinediones (TZDs), a new group of antidiabetic drugs, may modulate the proliferative and inflammatory cascades involved in atherosclerosis. Thus, an increasing totality of evidence suggests that TZDs may represent a unique and powerful research tool to find a common denominator underlying the pathophysiology and treatment of the metabolic cardiovascular risk factors associated with HIV infection.
将人类免疫缺陷病毒（HIV）蛋白酶抑制剂用作高效抗逆转录病毒疗法（HAART）的一部分，与动脉粥样硬化性血脂异常、胰岛素抵抗、高血压和内皮功能障碍有关，所有这些都会导致过早发生冠心病。这些异常似乎与HIV感染患者心血管事件的增加有关。据报道，用于HIV感染患者的抗糖尿病药物具有有益的代谢作用。噻唑烷二酮类药物（TZDs）是一类新型抗糖尿病药物，可能会调节动脉粥样硬化中涉及的增殖和炎症级联反应。因此，越来越多的证据表明，TZDs可能是一种独特而强大的研究工具，有助于找到与HIV感染相关的代谢性心血管危险因素的病理生理学和治疗方法的共同基础。
